Ross A. Soo

Research interests

Publications

• Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

  Journal of Clinical Oncology · 2024 · https://doi.org/10.1200/jco.24.00581

• Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

  The Lancet Respiratory Medicine · 2022 · https://doi.org/10.1016/s2213-2600(22)00437-4

• Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

  The Lancet Respiratory Medicine · 2020 · https://doi.org/10.1016/s2213-2600(20)30154-5

• The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer

  Journal of Thoracic Oncology · 2020 · 10.1016/j.jtho.2020.05.002

• Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.010

• Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial

  The Lancet Respiratory Medicine · 2020 · https://doi.org/10.1016/s2213-2600(20)30154-5

• Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

  Journal of Thoracic Oncology · 2020 · https://doi.org/10.1016/j.jtho.2020.03.028

• Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial

  The Lancet Oncology · 2019 · 10.1016/s1470-2045(19)30655-2

• ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.18.02236

• IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC.

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2018.36.18_suppl.lba9000

• Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

  Annals of Oncology · 2018 · https://doi.org/10.1093/annonc/mdy554

• Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

  The Lancet Oncology · 2018 · https://doi.org/10.1016/s1470-2045(18)30144-x

• Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30649-1

• Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies

  Cancer Treatment Reviews · 2018 · 10.1016/j.ctrv.2018.02.006

• Third generation EGFR TKIs: current data and future directions

  Molecular Cancer · 2018 · 10.1186/s12943-018-0778-0

• De-novo and acquired resistance to immune checkpoint targeting

  The Lancet Oncology · 2017 · 10.1016/s1470-2045(17)30607-1

• Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression

  Nature Communications · 2016 · https://doi.org/10.1038/ncomms11702

• Nivolumab in NSCLC: latest evidence and clinical potential

  Therapeutic Advances in Medical Oncology · 2015 · 10.1177/1758834014567470

• An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells

  The Analyst · 2014 · 10.1039/c4an00355a

• Clinical Validation of an Ultra High-Throughput Spiral Microfluidics for the Detection and Enrichment of Viable Circulating Tumor Cells

  PLoS ONE · 2014 · 10.1371/journal.pone.0099409

• Isolation and retrieval of circulating tumor cells using centrifugal forces

  Scientific Reports · 2013 · 10.1038/srep01259

• Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer

  Science Translational Medicine · 2013 · 10.1126/scitranslmed.3007205

• Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis

  Cell · 2012 · https://doi.org/10.1016/j.cell.2011.11.050

• Fibroblast Growth Factor Receptor 1 Gene Amplification Is Associated With Poor Survival and Cigarette Smoking Dosage in Patients With Resected Squamous Cell Lung Cancer

  Journal of Clinical Oncology · 2012 · https://doi.org/10.1200/jco.2012.43.8622

• Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation

  Molecular Cancer Therapeutics · 2012 · 10.1158/1535-7163.mct-12-0311

• A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

  Nature Medicine · 2012 · https://doi.org/10.1038/nm.2713

• Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement

  Cancer · 2011 · https://doi.org/10.1002/cncr.26311

Current projects

No projects listed.